Superworth

GLAUKOS price to sales ratio GKOS

Market value divided by revenue over the last twelve months, since 2016.

Today, Nov 2, 2026
23.0×
10-year median
11.6×
Against its 10-year history
98th
percentile: 0 is its lowest day, 100 its highest
10-year range
4.7× to 24.5×
Peer median
3.6×

GLAUKOS' price to sales ratio is 23.0× as of Nov 2, 2026.

That is above its ten-year median of 11.6×, higher than on 98% of days in the last ten years.

Over that time it ranged from 4.7× in Mar 2020 to 24.5× in Jan 2025.

The median for 10 medical instruments and supplies stocks of a similar size is 3.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far23.0×11.0×23.0×
202514.2×9.9×24.5×
202423.1×12.7×23.1×
202312.8×7.6×13.2×
20227.3×6.2×10.2×
20217.1×6.4×19.8×
202015.6×4.7×15.6×
20199.0×9.0×16.0×
201811.9×6.0×14.6×
20175.9×5.8×15.4×
201611.3×7.2×14.2×

Against its peers

Companies in Medical - Instruments & Supplies nearest GLAUKOS' size, closest first, today.

CompanyPrice to sales ratio
GKOSGLAUKOS23.0×
SOLVSolventum1.7×
PENPenumbra8.4×
COOCooper Companies2.8×
ALGNAlign Technology2.6×
GMEDGlobus Medical3.4×
PODDInsulet3.5×
MSAMSA Safety3.7×
WSTWest Pharmaceutical Services8.7×
RMDResMed5.7×
HAEHaemonetics4.0×
Peer median3.6×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on GLAUKOS

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.